Rosacea – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Rosacea – Pipeline Review, H1 2017’, provides an overview of the Rosacea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rosacea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Rosacea

The report reviews pipeline therapeutics for Rosacea by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rosacea therapeutics and enlists all their major and minor projects

The report assesses Rosacea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rosacea

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rosacea

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amorepacific Corp

BioPharmX Inc

Cutanea Life Sciences Inc

ELORAC Inc

Foamix Pharmaceuticals Ltd

Hovione FarmaCiencia SA

Promius Pharma LLC

Sol-Gel Technologies Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rosacea - Overview

Rosacea - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Rosacea - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rosacea - Companies Involved in Therapeutics Development

Amorepacific Corp

BioPharmX Inc

Cutanea Life Sciences Inc

ELORAC Inc

Foamix Pharmaceuticals Ltd

Hovione FarmaCiencia SA

Promius Pharma LLC

Sol-Gel Technologies Ltd

Rosacea - Drug Profiles

AC-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACUD-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzoyl peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carbamide peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DFD-29 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-220 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-0003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FMX-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itraconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

minocycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

minocycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omiganan pentahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rosacea - Dormant Projects

Rosacea - Discontinued Products

Rosacea - Product Development Milestones

Featured News & Press Releases

Jan 18, 2017: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study

Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients

Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea

Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea

May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea

May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study

May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea

Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea

Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK

Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission

Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea

Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso

Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33%

Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso

Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Rosacea, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Rosacea – Pipeline by Amorepacific Corp, H1 2017

Rosacea – Pipeline by BioPharmX Inc, H1 2017

Rosacea – Pipeline by Cutanea Life Sciences Inc, H1 2017

Rosacea – Pipeline by ELORAC Inc, H1 2017

Rosacea – Pipeline by Foamix Pharmaceuticals Ltd, H1 2017

Rosacea – Pipeline by Hovione FarmaCiencia SA, H1 2017

Rosacea – Pipeline by Promius Pharma LLC, H1 2017

Rosacea – Pipeline by Sol-Gel Technologies Ltd, H1 2017

Rosacea – Dormant Projects, H1 2017

Rosacea – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Rosacea, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports